A groundbreaking injectable HIV prevention drug will be available for just $40 a year in over 100 countries by 2027, thanks to agreements between Unitaid, the Gates Foundation, and Indian pharmaceutical companies.
A groundbreaking partnership aims to provide low-cost lenacapavir to millions at risk of HIV in low- and middle-income countries, potentially transforming HIV prevention efforts worldwide.
The EU has recommended lenacapavir, an injectable drug for HIV prevention, which could drastically reduce transmission rates. With nearly 100% effectiveness, it promises a new era in combating HIV.
The European Medicines Agency has recommended the approval of lenacapavir, a twice-yearly injectable drug that could revolutionize HIV prevention and significantly reduce transmission rates globally.
The FDA has approved lenacapavir, a groundbreaking antiviral drug for HIV prevention developed by biochemist Wesley Sundquist. Learn how this drug could change the future of HIV treatment and prevention.
Today, the U.S. Supreme Court hears a pivotal case on Obamacare's preventive care mandate, with major implications for health coverage, including HIV prevention drugs like PrEP. Conservative employers argue the mandate is unconstitutional, raising fears about the future of essential health services.
